The U.S. logged fewer than 30 measles cases this week as Ohio health officials confirmed three outbreaks in two counties were over.
FDA approves pembrolizumab for resectable head and neck cancer with PD-L1 expression
Pembrolizumab, an immune checkpoint inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with resectable locally advanced head and neck squamous cell carcinoma whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test.
2020 to 2022 saw nearly 2 million annual emergency room visits for dental issues
Tooth disorders accounted for an annual average of 1,944,000 emergency department visits during 2020 to 2022, according to a June data brief published by the National Center for Health Statistics.
Evolutionary model for antibiotic resistance reveals dose timing critical to care
Cleveland Clinic researchers are working to improve the way we use evolutionary modeling to understand drug resistance. The study, published in Science Advances, uses a new type of evolutionary model called a “fitness seascape” to incorporate a patient’s dosage schedule into models that predict whether an infection will develop antibiotic resistance, and has found that inconsistent timing and missing early doses can lead to treatment failure.
Different genetic roots of autism may lead to shared brain activity and behaviors
New research from the University of Minnesota Medical School suggests that different genetic forms of autism may lead to similar patterns in brain activity and behavior. The findings were recently published in Nature Neuroscience.
Synergistic drug combinations explored for systemic sclerosis vasodilation
It is known that vasculopathy plays a pivotal role in the pathogenesis of systemic sclerosis (SSc). Vasoactive vasodilating drugs (VVD) are an option. The most recent treatment recommendations from EULAR—The European Alliance of Associations for Rheumatology—note that advances in vasculopathy management for patients with SSc emphasize a treatment continuum for the use of various VVD, but also stress the need for trials to look for potential synergistic combinations as well as high-quality real-world data to build the evidence. New data shared at the 2025 EULAR congress in Barcelona may take a step in that direction.
Children with acute allergic reactions often spend unnecessary time in hospitals
Be it peanuts or other triggers, many families live with the day-to-day risk that their child might experience a sudden and scary allergic reaction. Pediatric emergency department visits in the United States to treat acute allergic reactions more than tripled from 2008 to 2016.
Blocking CD200R1 protein offers new strategy for treatment-resistant blood cancers
Immunotherapy has revolutionized cancer treatment by mobilizing the immune system to attack tumor cells. Major advances, such as immune checkpoint inhibitors (notably against the PD-1 protein), have produced impressive results against certain types of cancer, including melanoma and kidney cancer.
Study reveals risk factors for spinal deterioration in r-axSpA
Axial spondyloarthritis (axSpA) is a chronic inflammatory rheumatic musculoskeletal disease that predominantly affects the axial skeleton. axSpA is an umbrella term that comprises the whole spectrum of patients with and without radiographic sacroiliitis, and joint ASAS/EULAR recommendations were published in 2022.
Studies show nurses play a critical role for people with rheumatic musculoskeletal diseases
EULAR—The European Alliance of Associations for Rheumatology—believes that nurses are an important part of the health care team, especially for providing evidence-based care and endorsing shared decision-making in consultation with the patient. This is also important considering the shortage of rheumatologists in Europe, which means delegation is necessary.